Overall, auto-Abs neutralizing IFN-α2 and/or IFN-ω were found at the onset of disease in 10 of 42 patients (24%) with breakthrough COVID-19 who suffered from hypoxemic pneumonia, despite having a normal antibody response to an mRNA vaccine. Here, IFNA2 is linked to pneumonia.